Tirzepatid is the world’s first synthetic polypeptide drug that acts as a dual agonist of GLP-1 and GIP receptors. Its mechanism for regulating blood glucose involves activating GLP-1 receptors to promote insulin secretion and inhibit glucagon release, while activating GIP receptors enhances insulin sensitivity and secretion. Additionally, Tirzepatid delays gastric emptying, increases satiety to reduce food intake, aids in weight loss, and elevates adiponectin levels to improve insulin sensitivity and lipid metabolism. Clinical trials confirm that it controls blood glucose more effectively than single GLP-1 agonists, significantly reducing hemoglobin A1c levels, and excels in weight loss with an average weight reduction exceeding 20%, making it applicable for obesity treatment. Its once-weekly injection regimen improves patient compliance, has fewer side effects, positively impacts blood pressure and lipid profiles, and demonstrates potential cardioprotective effects.

The peptide will be provided as lyophilized powder to ensure maximum stability.